Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2012
The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)
Epistemonikos ID: 8ead6053685b94b363d6116bdd3c17c2822d9757
First added on: Jan 21, 2022